Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 2/20 | 0.52 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.48 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | RORC | P51449 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | NOS2 | P35228 | 6/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.41 |
| ▸ | IGLV6-57 | P01721 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4197135 | 0.86 | AR (0.48) | ARS1PR3MRGPRX4KDM4EALDH1A1 | |
| SCHEMBL4207181 | 0.82 | SLC6A4 (0.49) | ARS1PR3MRGPRX4NOS2CYP2D6 | |
| SCHEMBL13779687 | 0.82 | AR (0.59) | ARMRGPRX4KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL177449 | 0.81 | AR (0.53) | ARMRGPRX4KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL4206255 | 0.80 | AR (0.57) | ARMRGPRX4KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL4198733 | 0.79 | AR (0.58) | AR | |
| SCHEMBL4193058 | 0.79 | AR (0.58) | AR | |
| SCHEMBL4193056 | 0.79 | AR (0.58) | AR | |
| SCHEMBL4200960 | 0.78 | SLC6A2 (0.49) | ARS1PR3CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL27376804 | 0.77 | AR (0.52) | ARMRGPRX4KDM4EALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090170886-A1 | ANDROGEN MODULATORS | PFIZER INC | 2009-07-02 | — | — | US | disclosed |
| US-20090170886-A1 | ANDROGEN MODULATORS | PFIZER INC | 2009-07-02 | — | — | US | disclosed |
| US-20090170886-A1 | ANDROGEN MODULATORS | PFIZER INC | 2009-07-02 | — | — | US | disclosed |
| WO-2007017754-A2 | ANDROGEN MODULATORS | WARNER-LAMBERT COMPANY LLC (US) | 2007-02-15 | — | — | WO | disclosed |
| EP-1027316-B1 | SYNTHESIS OF ARYL ETHERS, METHODS AND REAGENTS RELATED THERETO | MASSACHUSETTS INST TECHNOLOGY (US) | 2003-05-21 | — | — | EP | disclosed |
| EP-1254884-A2 | Preparation of vinyl ethers from alcohols and alkenes | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2002-11-06 | — | — | EP | disclosed |
| EP-1245553-A2 | Palladium-catalysed synthesis of aryl ethers | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2002-10-02 | — | — | EP | disclosed |
| EP-1027316-A1 | SYNTHESIS OF ARYL ETHERS, METHODS AND REAGENTS RELATED THERETO | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2000-08-16 | — | — | EP | disclosed |
| WO-1998015515-A1 | SYNTHESIS OF ARYL ETHERS, METHODS AND REAGENTS RELATED THERETO | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1998-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170886-A1 | ANDROGEN MODULATORS | AR, NR5A1, SHBG | AR 1/4885S1PR3 3142/4885MRGPRX4 1139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.